Clinical Trials Browser

Withdrawn × selinexor × Clear all

NCT04607772 2025-10-03

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2 Withdrawn

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05820763 2024-07-10

Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant

Phase 2 Withdrawn

Multiple Myeloma, Neoplasm, Residual

NCT05952687 2024-03-27

Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors

Phase 1 Withdrawn

Central Nervous System Neoplasms, Rhabdoid Tumor

NCT02389543 2023-01-26

SLAM

Phase 1/2 Withdrawn

Multiple Myeloma, Recurrence

NCT02628704 2023-01-26

SCORE

Phase 2 Withdrawn

Multiple Myeloma

NCT05170789 2022-05-04

ESdRRMM

Phase 2 Withdrawn

Multiple Myeloma, Recurrence

NCT05177276 2022-01-04

Selinexor Combination Ph 1 Study

Phase 1/2 Withdrawn

Other solid neoplasm

Solid Tumor Malignancy

NCT03880123 2020-11-27

Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma

Phase 1 Withdrawn

Liposarcoma, Sarcoma, Sarcoma, Ewing, Sarcoma, Alveolar Soft Part, Neurofibrosarcoma

NCT02536495 2015-10-30

Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer

Phase 1/2 Withdrawn

Recurrent Squamous Cell Lung Carcinoma